|
|
(6 intermediate revisions by the same user not shown) |
Line 9: |
Line 9: |
| | docket = 05000608 | | | docket = 05000608 |
| | license number = | | | license number = |
| | contact person = Montgomery C K, NRR/DLP, 415-3398 | | | contact person = Montgomery C, NRR/DLP, 415-3398 |
| | case reference number = CAC MF1395 | | | case reference number = CAC MF1395 |
| | package number = ML17362A105 -Pkg. | | | package number = ML17362A105 -Pkg. |
Line 19: |
Line 19: |
|
| |
|
| =Text= | | =Text= |
| {{#Wiki_filter:UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 January 9, 2018 Dr. Gregory Piefer Chief Executive Officer Shine Medical Technologies 2555 Industrial Drive Monona, WI 53713 SUBJECT: SHINE MEDICAL TECHNOLOGIES - REGULATORY INFORMATION CONFERENCE 2018 INVITATION LETTER, SPEAKER CONFIRMATION FORM, AND EXTERNAL AGREEMENT FORM (CAC MF1395) | | {{#Wiki_filter:UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 January 9, 2018 Dr. Gregory Piefer Chief Executive Officer Shine Medical Technologies 2555 Industrial Drive Monona, WI 53713 |
| | |
| | ==SUBJECT:== |
| | SHINE MEDICAL TECHNOLOGIES - REGULATORY INFORMATION CONFERENCE 2018 INVITATION LETTER, SPEAKER CONFIRMATION FORM, AND EXTERNAL AGREEMENT FORM (CAC MF1395) |
|
| |
|
| ==Dear Dr. Piefer:== | | ==Dear Dr. Piefer:== |
|
| |
|
| It is my pleasure to invite you to participate as a speaker at NRC's 30th Regulatory Information Conference (RIC). The RIC will be held on March 13-15, 2018, at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. | | It is my pleasure to invite you to participate as a speaker at NRCs 30th Regulatory Information Conference (RIC). The RIC will be held on March 13-15, 2018, at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. |
| | This 3-day annual conference is co-sponsored by the Office of Nuclear Reactor Regulation and the Office of Nuclear Regulatory Research, and brings together more than 3,000 participants from over 30 countries representing interested parties from government, industry, international agencies, other interested stakeholders, and members of the public. The RIC fosters communication about U.S. Nuclear Regulatory Commission (NRC) activities, and offers a valuable forum to share perspectives on technical issues and other matters facing the nuclear industry. |
| | Your participation as a technical session panelist will bring great value to our session entitled, Progress Toward a Reliable Domestic Supply of Molybdenum-99 [Mo-99], which I will be chairing. The session will be held on Wednesday, March 14, 2018, from 1:30 p.m. to 3:00 p.m. |
| | We would like to give participants an opportunity to learn, What improvements are underway in construction inspection procedures, operation inspection procedures, guidance, and considerations of the impact of proposed rulemakings, on potential medical isotope facilities? This session details the progress toward licensing and regulating medical isotope facilities and shares the perspectives of regulators, licensee, the Department of Energy, and other stakeholders. I am anticipating that you can speak about recent SHINE activities addressing the future domestic production of Mo-99. |
|
| |
|
| This 3-day annual conference is co-sponsored by the Office of Nuclear Reactor Regulation and the Office of Nuclear Regulatory Research, and brings together more than 3,000 participants from over 30 countries representing interested parties from government, industry, international agencies, other interested stakeholders, and members of the public. The RIC fosters communication about U.S. Nuclear Regulatory Commission (NRC) activities, and offers a valuable forum to share perspectives on technical issues and other matters facing the nuclear industry. Your participation as a technical session panelist will bring great value to our session entitled, "Progress Toward a Reliable Domestic Supply of Molybdenum-99 [Mo-99]," which I will be chairing. The session will be held on Wednesday, March 14, 2018, from 1:30 p.m. to 3:00 p.m.
| | I hope you are able to accept this invitation. You can find RIC-related news and up-to-date conference information by navigating from the NRCs official public website at http://www.nrc.gov. To confirm your participation, please complete and return the enclosed RIC Speaker Confirmation Form and RIC External Speaker Agreement Form to Ms. Cindy Montgomery, our session coordinator, by January 16, 2018. Please contact Ms. Montgomery or me if you have questions. Ms. Montgomery can be reached on 301-415-3398 or Cindy.Montgomery@nrc.gov. |
| We would like to give participants an opportunity to learn, "What improvements are underway in construction inspection procedures, operation inspection procedures, guidance, and considerations of the impact of proposed rulemakings, on potential medical isotope facilities?" This session details the progress toward licensing and regulating medical isotope facilities and shares the perspectives of regulators, licensee, the Department of Energy, and other stakeholders. I am anticipating that you can speak about recent SHINE activities addressing the future domestic production of Mo-99.
| | Sincerely, |
| I hope you are able to accept this invitation. You can find RIC-related news and up-to-date conference information by navigating from the NRC's official public website at http://www.nrc.gov. To confirm your participation, please complete and return the enclosed RIC Speaker Confirmation Form and RIC External Speaker Agreement Form to Ms. Cindy Montgomery, our session coordinator, by January 16, 2018. Please contact Ms. Montgomery or me if you have questions. Ms. Montgomery can be reached on 301-415-3398 or Cindy.Montgomery@nrc.gov. Sincerely, /RA Linh Tran for/ Alexander Adams, Jr., Chief Research and Test Reactors Licensing Branch Division of Licensing Projects Office of Nuclear Reactor Regulation | | /RA Linh Tran for/ |
| | Alexander Adams, Jr., Chief Research and Test Reactors Licensing Branch Division of Licensing Projects Office of Nuclear Reactor Regulation Docket No. 50-608 |
|
| |
|
| Docket No. 50-608 Enclosures:
| | ==Enclosures:== |
| RIC Speaker Confirmation Form RIC External Speaker Agreement Form
| |
|
| |
|
| ==SUBJECT:==
| | RIC Speaker Confirmation Form RIC External Speaker Agreement Form |
| SHINE MEDICAL TECHNOLOGIES, LLC REGULATORY INFORMATION CONFERENCE 2018 INVITATION LETTER, SPEAKER CONFIRMATION FORM, AND EXTERNAL AGREEMENT FORM (CAC MF1395) DATE: JANUARY 9, 2017
| |
|
| |
|
| DISTRIBUTION: PUBLIC RidsNrrDlp SLynch, NRR RidsOgcMailCenter MBalazik, NRR LTran, NRR RidsACRS_MailCTR AAdams, NRR PRLB r/f RidsNrrDlpPrlb NParker, NRR RidsNrrDlpProb AMendiola, NRR ADAMS Accession No.: ML17362A083,Letter; ML17355A548 / ML17355A550 Forms; ML17362A105 -Pkg. *concurred via email NRR-088 OFFICE NRR/DLP/PRLB/PM NRR/DLP/PRLB/BC NRR/DLP/PRLB/PM NAME CMontgomery AAdams (LTran for) CMontgomery DATE 12/27/2017 1/9/2017 1/9/2017 OFFICIAL RECORD COPY
| | ML17362A083,Letter; ML17355A548 / ML17355A550 Forms; ML17362A105 -Pkg. *concurred via email NRR-088 OFFICE NRR/DLP/PRLB/PM NRR/DLP/PRLB/BC NRR/DLP/PRLB/PM NAME CMontgomery AAdams CMontgomery (LTran for) |
| }} | | DATE 12/27/2017 1/9/2017 1/9/2017}} |
|
---|
Category:Letter
MONTHYEARML24128A2162024-05-0707 May 2024 Shine Technologies, LLC, Submittal of Annual Financial Report ML24047A0392024-02-16016 February 2024 Shine Technologies, LLC - Periodic Report Required by the License Conditions in Section 3.D.(1) of CPMIF-001 ML23229A0202023-08-17017 August 2023 Periodic Report Required by the License Conditions in Section 3.D.(1) of CPMIF-001 ML23087A2272023-05-0505 May 2023 Shine Technologies, LLC - Issuance of Amendment No. 4 to Construction Permit No. CPMIF-001 for the Receipt and Possession of Contained Special Nuclear Material ML23086C0502023-04-27027 April 2023 Shine Technologies, LLC - Letter, Environmental Assessment and Finding of No Significant Impact ML23088A3382023-04-0505 April 2023 Shine Technologies, LLC - Review of the Physical Security Plan in Support of an Operating License for a Medical Radioisotope Production Facility ML23010A1982023-02-24024 February 2023 Shine Technologies, LLC - Letter: Safety Evaluation Report for the Shine Medical Radioisotope Production Facility Operating License Application ML23048A2442023-02-17017 February 2023 Shine Technologies, LLC Request to Amend Construction Permit No. CPMIF-001 Response to Request for Additional Information ML23010A2382023-02-0303 February 2023 Shine Technologies, LLC - Individual Notice of Consideration FRN Letter ML23034A1872023-02-0303 February 2023 Shine Medical Technologies, LLC Notice of Availability of Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility (Docket Number: 50-608) ML23023A0922023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23023A0942023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23023A0862023-02-0202 February 2023 Notice of Availability of the Environmental Impact Statement Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML23024A1682023-02-0101 February 2023 Letter to Ken Westlake, EPA Region 5 - Issuance of Final EIS Supplement Related to the Operating License ML22287A1852023-02-0101 February 2023 Shine Technologies, LLC Regulatory Report on the Audit of Phased Startup Operations Application Supplement ML23024A1742023-02-0101 February 2023 Dr. Gregory Piefer, Chief Executive Officer - Issuance of Final EIS Supplement Related to the Operating License ML22308A2332023-01-0909 January 2023 Shine Technologies LLC - Regulatory Audit Report for Chapter 8 - Irradiation Facility and Radioisotope Production Facility Electrical Power Systems ML22347A2142023-01-0404 January 2023 Shine Technologies LLC - Regulatory Audit Report for I&C Combined Sessions ML22356A1932022-12-22022 December 2022 Shine Technologies, LLC Application for an Operating License - Response to Request for Confirmatory Information ML22347A1772022-12-14014 December 2022 Shine Technologies LLC - Regulatory Audit Report for Programmable Logic Lifecycle ML22301A1492022-12-0707 December 2022 Shine Technologies, LLC - Regulatory Audit Report for Chapter 13 - Accident Analysis and Criticality Safety ML22322A2122022-12-0202 December 2022 Shine Medical Technologies - Cybersecurity Audit Summary Report ML22322A2232022-12-0202 December 2022 Shine Medical Technologies - Fire Protection Audit Summary Report ML22348A0672022-12-0101 December 2022 Shine Technologies, LLC - Request for Confirmatory Information Related to Instrumentation and Control Systems ML22335A5722022-12-0101 December 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22292A3192022-11-30030 November 2022 Shine Medical Technologies, LLC Issuance of Order and Amendment No. 3 to Construction Permit No. CPMIF-001 ML22318A1782022-11-14014 November 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22304A1262022-10-31031 October 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22279A9512022-10-0606 October 2022 Shine Technologies, LLC Request to Amend Construction Permit No. CPMIF-001 ML22271A9632022-09-28028 September 2022 Shine Technologies, LLC Application for an Operating License Supplement No. 31 Revision to the Phased Startup Operations Application Supplement ML22263A3442022-09-20020 September 2022 Shine Technologies, LLC Application for an Operating License - Response to Request for Additional Information ML22263A0272022-09-19019 September 2022 Shine Technologies, LLC - Application for an Operating License - Response to Request for Confirmatory Information ML22220A2612022-09-12012 September 2022 Shine Technologies LLC - Regulatory Report on the Audit Chapter 14, Technical Specifications ML22251A3272022-09-0808 September 2022 Shine Technologies, LLC Application for an Operating License Revision 1 of Shine Response to Requests for Additional Information 7-38, 7-40, and 7-48 ML22249A1252022-08-31031 August 2022 Shine Technologies, LLC Final Safety Analysis Report - Application for an Operating License Supplement No. 30, Cover Letter ML22105A1102022-08-26026 August 2022 Shine Medical Technologies LLC - Request for Additional Information Related to the OGC Review of Phrase Approach ML22061A2122022-08-24024 August 2022 Shine Medical Technologies LLC - Regulatory Audit Plan for Phased Approach - Session 1 ML22187A1342022-08-0101 August 2022 Shine Technologies, LLC - Update to Operating License Application Technical Review Schedule ML22213A0492022-08-0101 August 2022 Shine Technologies, LLC Application for an Operating License Response to Request for Confirmatory Information ML22206A2082022-07-27027 July 2022 Shine Medical Technologies, LLC - Request for Confirmatory Information Related to Radiation Protection Program and Waste Management ML22207A0062022-07-26026 July 2022 Shine Technologies, LLC Application for an Operating License Supplement No. 29 ML22202A4492022-07-21021 July 2022 Shine Technologies, LLC Operating License Application Supplement No. 28 - Submittal of a Revision to the Shine Emergency Plan ML22188A2412022-07-14014 July 2022 Meeting with Shine Medical Technologies, LLC (EPID No. L-2019-NEW-0004), to Discuss Development of Shine'S Cybersecurity Program for It'S Medical Isotope Production Facility ML22175A0392022-07-11011 July 2022 Letter to Reid Nelson, Achp Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22175A0542022-07-0808 July 2022 Letter to Gregory Piefer - Notice of Availability of the Draft EIS Supplement Related to the Operating License for the Shine Medical Isotope Production Facility ML22175A0912022-07-0808 July 2022 Notice of Availability and Request for Comments on the Draft Environmental Impact Statement Supplement Related to the Operating License for the Shine (Multiple Tribal Letters) ML22175A0772022-07-0808 July 2022 Letter to Daina Penkiunas - Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22175A0632022-07-0808 July 2022 Letter to Ken Westlake, EPA Region 5 - Notice of Availability and Request for Comments on the Draft EIS Supplement Related to the Operating License for the Shine Facility ML22188A1942022-07-0707 July 2022 Shine Technologies, LLC, Application for an Operating License Supplement No. 27 ML22188A0562022-07-0707 July 2022 Shine Technologies, LLC Operating License Application Supplement No. 26 Submittal of a Revision to the Shine Material Control and Accounting Plan 2024-05-07
[Table view] |
Text
UNITED STATES NUCLEAR REGULATORY COMMISSION WASHINGTON, D.C. 20555-0001 January 9, 2018 Dr. Gregory Piefer Chief Executive Officer Shine Medical Technologies 2555 Industrial Drive Monona, WI 53713
SUBJECT:
SHINE MEDICAL TECHNOLOGIES - REGULATORY INFORMATION CONFERENCE 2018 INVITATION LETTER, SPEAKER CONFIRMATION FORM, AND EXTERNAL AGREEMENT FORM (CAC MF1395)
Dear Dr. Piefer:
It is my pleasure to invite you to participate as a speaker at NRCs 30th Regulatory Information Conference (RIC). The RIC will be held on March 13-15, 2018, at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.
This 3-day annual conference is co-sponsored by the Office of Nuclear Reactor Regulation and the Office of Nuclear Regulatory Research, and brings together more than 3,000 participants from over 30 countries representing interested parties from government, industry, international agencies, other interested stakeholders, and members of the public. The RIC fosters communication about U.S. Nuclear Regulatory Commission (NRC) activities, and offers a valuable forum to share perspectives on technical issues and other matters facing the nuclear industry.
Your participation as a technical session panelist will bring great value to our session entitled, Progress Toward a Reliable Domestic Supply of Molybdenum-99 [Mo-99], which I will be chairing. The session will be held on Wednesday, March 14, 2018, from 1:30 p.m. to 3:00 p.m.
We would like to give participants an opportunity to learn, What improvements are underway in construction inspection procedures, operation inspection procedures, guidance, and considerations of the impact of proposed rulemakings, on potential medical isotope facilities? This session details the progress toward licensing and regulating medical isotope facilities and shares the perspectives of regulators, licensee, the Department of Energy, and other stakeholders. I am anticipating that you can speak about recent SHINE activities addressing the future domestic production of Mo-99.
I hope you are able to accept this invitation. You can find RIC-related news and up-to-date conference information by navigating from the NRCs official public website at http://www.nrc.gov. To confirm your participation, please complete and return the enclosed RIC Speaker Confirmation Form and RIC External Speaker Agreement Form to Ms. Cindy Montgomery, our session coordinator, by January 16, 2018. Please contact Ms. Montgomery or me if you have questions. Ms. Montgomery can be reached on 301-415-3398 or Cindy.Montgomery@nrc.gov.
Sincerely,
/RA Linh Tran for/
Alexander Adams, Jr., Chief Research and Test Reactors Licensing Branch Division of Licensing Projects Office of Nuclear Reactor Regulation Docket No. 50-608
Enclosures:
RIC Speaker Confirmation Form RIC External Speaker Agreement Form
ML17362A083,Letter; ML17355A548 / ML17355A550 Forms; ML17362A105 -Pkg. *concurred via email NRR-088 OFFICE NRR/DLP/PRLB/PM NRR/DLP/PRLB/BC NRR/DLP/PRLB/PM NAME CMontgomery AAdams CMontgomery (LTran for)
DATE 12/27/2017 1/9/2017 1/9/2017